Telix Pharmaceuticals Limited (NASDAQ:TLX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) have been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $21.1250.

Several research firms have recently weighed in on TLX. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research note on Monday, April 13th. Wedbush reiterated an “outperform” rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Monday, April 13th. Wall Street Zen upgraded Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, April 11th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Monday, April 20th.

Insider Buying and Selling

In other Telix Pharmaceuticals news, CEO Christian Behrenbruch purchased 33,435 shares of the firm’s stock in a transaction that occurred on Wednesday, April 29th. The shares were acquired at an average cost of $14.87 per share, for a total transaction of $497,178.45. Following the transaction, the chief executive officer directly owned 20,742,935 shares in the company, valued at approximately $308,447,443.45. The trade was a 0.16% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link.

Institutional Investors Weigh In On Telix Pharmaceuticals

Large investors have recently bought and sold shares of the business. Rhumbline Advisers grew its position in Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after acquiring an additional 1,392 shares during the last quarter. Bank of America Corp DE grew its position in Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares during the last quarter. XTX Topco Ltd bought a new stake in Telix Pharmaceuticals during the 4th quarter worth approximately $89,000. XY Capital Ltd bought a new stake in Telix Pharmaceuticals during the 1st quarter worth approximately $120,000. Finally, IHT Wealth Management LLC bought a new stake in Telix Pharmaceuticals during the 2nd quarter worth approximately $213,000.

Telix Pharmaceuticals Stock Down 1.8%

TLX stock opened at $10.66 on Friday. Telix Pharmaceuticals has a 1-year low of $6.28 and a 1-year high of $16.98. The business’s 50 day moving average is $10.12 and its 200-day moving average is $8.76. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.